|
【结 构 式】 
|
【分子编号】40015 【品名】3-bromo-2-methyl-1-propene 【CA登记号】1458-98-6 |
【 分 子 式 】C4H7Br 【 分 子 量 】135.00358 【元素组成】C 35.59% H 5.23% Br 59.19% |
合成路线1
该中间体在本合成路线中的序号：(III)Catalytic hydrogenation of methyl isobutyrylacetate (I) in the presence of chiral ruthenium catalyst afforded the (S)-hydroxy ester (II). Subsequent alkylation of the lithium enolate of (II) with 3-bromo-2-methyl-1-propene (III) proceeded with diastereoselectivity, yielding (IV). The olefin double bond of (IV) was then hydrogenated over Pd/C to provide the saturated compound (V). After basic hydrolysis of the methyl ester group of (V), the resultant carboxylic acid (VI) was coupled to O-tetrahydropyranylhydroxylamine (VII) to furnish the tetrahydropyranyl-protected hydroxamate (VIII). Conversion of (VIII) into the corresponding mesylate, followed by cyclization under basic conditions, gave rise to the azetidinone (IX). Further azetidinone ring opening under conditions of basic hydrolysis generated the N-hydroxyaminoacid derivative (X). This was converted to the formamide (XI) upon treatment with formic acetic anhydride in pyridine.
| 【1】 Chan, J.H.; Bubacz, D.G.; Andersen, M.W.; McDougald, D.L.; Stanford, J.B.; Andrews, R.C.; Gaul, M.D.; Rabinowitz, M.H.; Musso, D.L.; Cowan, D.J.; Wiethe, R.W. (GlaxoSmithKline plc); Reverse hydroxamate derivs. as metalloprotease inhibitors. EP 1019386; JP 2001513767; WO 9838179 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 43331 | methyl 4-methyl-3-oxopentanoate | 42558-54-3 | C7H12O3 | 详情 | 详情 |
| (II) | 52102 | methyl (3S)-3-hydroxy-4-methylpentanoate | C7H14O3 | 详情 | 详情 | |
| (III) | 40015 | 3-bromo-2-methyl-1-propene | 1458-98-6 | C4H7Br | 详情 | 详情 |
| (IV) | 52103 | methyl (2R)-2-[(1R)-1-hydroxy-2-methylpropyl]-4-methyl-4-pentenoate | C11H20O3 | 详情 | 详情 | |
| (V) | 52104 | methyl (2R,3R)-3-hydroxy-2-isobutyl-4-methylpentanoate | C11H22O3 | 详情 | 详情 | |
| (VI) | 52105 | (2R,3R)-3-hydroxy-2-isobutyl-4-methylpentanoic acid | C10H20O3 | 详情 | 详情 | |
| (VII) | 52106 | 2-(aminooxy)tetrahydro-2H-pyran; O-tetrahydro-2H-pyran-2-ylhydroxylamine | C5H11NO2 | 详情 | 详情 | |
| (VIII) | 52107 | (2R,3R)-3-hydroxy-2-isobutyl-4-methyl-N-(tetrahydro-2H-pyran-2-yloxy)pentanamide | C15H29NO4 | 详情 | 详情 | |
| (IX) | 52108 | (3R,4S)-3-isobutyl-4-isopropyl-1-(tetrahydro-2H-pyran-2-yloxy)-2-azetidinone | C15H27NO3 | 详情 | 详情 | |
| (X) | 52109 | (2R,3S)-2-isobutyl-4-methyl-3-[(tetrahydro-2H-pyran-2-yloxy)amino]pentanoic acid | C15H29NO4 | 详情 | 详情 | |
| (XI) | 52110 | (2R,3S)-3-[formyl(tetrahydro-2H-pyran-2-yloxy)amino]-2-isobutyl-4-methylpentanoic acid | C16H29NO5 | 详情 | 详情 |
合成路线2
该中间体在本合成路线中的序号：(III)2-Pyrrolidinone (I) was protected as the N-Boc derivative (II) and then alkylated with 3-bromo-2-methylpropene (III) in the presence of LDA to yield (IV). Further alkylation of (IV) with tert-butyl bromoacetate gave the dialkylated pyrrolidinone (V). Catalytic hydrogenation of the 2-methylpropenyl substituent of (V) produced the racemic isobutyl analogue (VI), which was resolved by means of chiral HPLC. The desired (S)-enantiomer (VII) was deprotected by treatment with magnesium ethoxide, affording pyrrolidinone (VIII). N-Alkylation of the pyrrolidinone (VIII) with triflate (IX) furnished adduct (X), which was hydrolyzed to carboxylic acid (XI) with methanolic NaOH. After activation of (XI) with carbonyl diimidazole, coupling with methylamine gave rise to amide (XII). Cleavage of the tert-butyl ester group of (XII) employing trifluoroacetic acid produced carboxylic acid (XIII). This was finally coupled with hydroxylamine using EDC and HOBt.
| 【1】 Jacobsen, E.J. (Pharmacia & Upjohn AB); Hydroxamic acid derivs. for use with the treatment of diseases related to connective tissue degradation. EP 0898562; JP 2000506163; US 5712300; WO 9732846 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| 11021 | Methanamine; Methylamine | 74-89-5 | CH5N | 详情 | 详情 | |
| 17430 | 2-Bromoacetic acid tert-butyl ester; tert-butyl 2-bromoacetate; tert-Butyl bromoacetate | 5292-43-3 | C6H11BrO2 | 详情 | 详情 | |
| (I) | 27397 | 2-Pyrrolidinone | 616-45-5 | C4H7NO | 详情 | 详情 |
| (II) | 40014 | tert-butyl 2-oxo-1-pyrrolidinecarboxylate | C9H15NO3 | 详情 | 详情 | |
| (III) | 40015 | 3-bromo-2-methyl-1-propene | 1458-98-6 | C4H7Br | 详情 | 详情 |
| (IV) | 40016 | tert-butyl 3-(2-methyl-2-propenyl)-2-oxo-1-pyrrolidinecarboxylate | C13H21NO3 | 详情 | 详情 | |
| (V) | 40017 | tert-butyl 3-[2-(tert-butoxy)-2-oxoethyl]-3-(2-methyl-2-propenyl)-2-oxo-1-pyrrolidinecarboxylate | C19H31NO5 | 详情 | 详情 | |
| (VI) | 40018 | tert-butyl 3-[2-(tert-butoxy)-2-oxoethyl]-3-isobutyl-2-oxo-1-pyrrolidinecarboxylate | C19H33NO5 | 详情 | 详情 | |
| (VII) | 40019 | tert-butyl (3S)-3-[2-(tert-butoxy)-2-oxoethyl]-3-isobutyl-2-oxo-1-pyrrolidinecarboxylate | C19H33NO5 | 详情 | 详情 | |
| (VIII) | 40020 | tert-butyl 2-[(3S)-3-isobutyl-2-oxopyrrolidinyl]acetate | C14H25NO3 | 详情 | 详情 | |
| (IX) | 40025 | methyl (2R)-2-cyclohexyl-2-[[(trifluoromethyl)sulfonyl]oxy]ethanoate | C10H15F3O5S | 详情 | 详情 | |
| (X) | 40021 | methyl (2S)-2-[(3S)-3-[2-(tert-butoxy)-2-oxoethyl]-3-isobutyl-2-oxopyrrolidinyl]-2-cyclohexylethanoate | C23H39NO5 | 详情 | 详情 | |
| (XI) | 40022 | (2S)-2-[(3S)-3-[2-(tert-butoxy)-2-oxoethyl]-3-isobutyl-2-oxopyrrolidinyl]-2-cyclohexylethanoic acid | C22H37NO5 | 详情 | 详情 | |
| (XII) | 40023 | tert-butyl 2-[(3S)-1-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-3-isobutyl-2-oxopyrrolidinyl]acetate | C23H40N2O4 | 详情 | 详情 | |
| (XIII) | 40024 | 2-[(3S)-1-[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]-3-isobutyl-2-oxopyrrolidinyl]acetic acid | C19H32N2O4 | 详情 | 详情 |
合成路线3
该中间体在本合成路线中的序号：(III)2-Pyrrolidinone (I) was protected as the N-Boc derivative (II) and then alkylated with 3-bromo-2-methylpropene (III) in the presence of LDA to yield (IV). Further alkylation of (IV) with tert-butyl bromoacetate gave the dialkylated pyrrolidinone (V). Catalytic hydrogenation of the 2-methylpropenyl substituent of (V) produced the racemic isobutyl analogue (VI), which was resolved by means of chiral HPLC. The desired (S)-enantiomer (VII) was deprotected by treatment with magnesium ethoxide, affording pyrrolidinone (VIII). Triflate (XI) was obtained from D-phenyllactic acid (IX) by formation of the methyl ester (X) upon treatment with iodomethane, followed by reaction with trifluoromethanesulfonic anhydride and pyridine. N-Alkylation of the pyrrolidinone (VIII) with triflate (XI) furnished adduct (XII), which was hydrolyzed to carboxylic acid (XIII) with methanolic NaOH. After activation of (XIII) with carbonyl diimidazole, coupling with methylamine gave rise to amide (XIV). Cleavage of the tert-butyl ester group of (XIV) employing trifluoroacetic acid produced carboxylic acid (XV). This was finally coupled with hydroxylamine using EDC and HOBt.
| 【1】 Jacobsen, E.J. (Pharmacia & Upjohn AB); Hydroxamic acid derivs. for use with the treatment of diseases related to connective tissue degradation. EP 0898562; JP 2000506163; US 5712300; WO 9732846 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| 11021 | Methanamine; Methylamine | 74-89-5 | CH5N | 详情 | 详情 | |
| 17430 | 2-Bromoacetic acid tert-butyl ester; tert-butyl 2-bromoacetate; tert-Butyl bromoacetate | 5292-43-3 | C6H11BrO2 | 详情 | 详情 | |
| (I) | 27397 | 2-Pyrrolidinone | 616-45-5 | C4H7NO | 详情 | 详情 |
| (II) | 40014 | tert-butyl 2-oxo-1-pyrrolidinecarboxylate | C9H15NO3 | 详情 | 详情 | |
| (III) | 40015 | 3-bromo-2-methyl-1-propene | 1458-98-6 | C4H7Br | 详情 | 详情 |
| (IV) | 40016 | tert-butyl 3-(2-methyl-2-propenyl)-2-oxo-1-pyrrolidinecarboxylate | C13H21NO3 | 详情 | 详情 | |
| (V) | 40017 | tert-butyl 3-[2-(tert-butoxy)-2-oxoethyl]-3-(2-methyl-2-propenyl)-2-oxo-1-pyrrolidinecarboxylate | C19H31NO5 | 详情 | 详情 | |
| (VI) | 40018 | tert-butyl 3-[2-(tert-butoxy)-2-oxoethyl]-3-isobutyl-2-oxo-1-pyrrolidinecarboxylate | C19H33NO5 | 详情 | 详情 | |
| (VII) | 40019 | tert-butyl (3S)-3-[2-(tert-butoxy)-2-oxoethyl]-3-isobutyl-2-oxo-1-pyrrolidinecarboxylate | C19H33NO5 | 详情 | 详情 | |
| (VIII) | 40020 | tert-butyl 2-[(3S)-3-isobutyl-2-oxopyrrolidinyl]acetate | C14H25NO3 | 详情 | 详情 | |
| (IX) | 40026 | (2R)-2-hydroxy-3-phenylpropionic acid | 7326-19-4 | C9H10O3 | 详情 | 详情 |
| (X) | 13878 | methyl (2R)-2-hydroxy-3-phenylpropanoate | C10H12O3 | 详情 | 详情 | |
| (XI) | 40027 | methyl (2R)-3-phenyl-2-[[(trifluoromethyl)sulfonyl]oxy]propanoate | C11H11F3O5S | 详情 | 详情 | |
| (XII) | 40028 | methyl (2S)-2-[(3S)-3-[2-(tert-butoxy)-2-oxoethyl]-3-isobutyl-2-oxopyrrolidinyl]-3-phenylpropanoate | C24H35NO5 | 详情 | 详情 | |
| (XIII) | 40029 | (2S)-2-[(3S)-3-[2-(tert-butoxy)-2-oxoethyl]-3-isobutyl-2-oxopyrrolidinyl]-3-phenylpropionic acid | C23H33NO5 | 详情 | 详情 | |
| (XIV) | 40030 | tert-butyl 2-[(3S)-1-[(1S)-1-benzyl-2-(methylamino)-2-oxoethyl]-3-isobutyl-2-oxopyrrolidinyl]acetate | C24H36N2O4 | 详情 | 详情 | |
| (XV) | 40031 | 2-[(3S)-1-[(1S)-1-benzyl-2-(methylamino)-2-oxoethyl]-3-isobutyl-2-oxopyrrolidinyl]acetic acid | C20H28N2O4 | 详情 | 详情 |
合成路线4
该中间体在本合成路线中的序号：(III)Hydrogenation of methyl butyrylacetate (I) in the presence of the chiral catalyst [RuCl2(BINAP)]2.Et3N furnished the (R)-hydroxyester (II). Alkylation of (II) with 3-bromo-2-methyl-1-propene (III) in the presence of lithium diisopropylamide gave the isobutenyl derivative (IV), which was further hydrogenated to (V) in the presence of Pd/C. After basic hydrolysis of the methyl ester of (V), the resulting carboxylic acid (VI) was coupled with 2-tetrahydropyranyloxyamine by means of EDC to provide the tetrahydropyranyl-protected hydroxamic acid (VII). Mesylation of the free hydroxyl group of (VII) to give (VIII), followed by its cyclization in the presence of potassium carbonate, gave rise to the azetidinone (IX). Opening of the lactam ring of (IX) with NaOH afforded the protected hydroxyamino acid (X). Then, formylation of the amino group with formic acetic anhydride in pyridine provided intermediate (XI).
| 【1】 Wiethe, R.W.; Andrews, R.C.; Rabinowitz, M.H.; Musso, D.L.; Chan, J.H.; McDougald, D.L.; Gaul, M.D.; Cowan, D.J.; Stanford, J.B.; Babacz, D.G.; Andersen, M.W. (Glaxo Group Ltd.); Formamide cpds. as therapeutic agents. US 6191150; WO 0012466 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 44115 | methyl 3-oxohexanoate | 30414-54-1 | C7H12O3 | 详情 | 详情 |
| (II) | 44116 | methyl (3R)-3-hydroxyhexanoate | C7H14O3 | 详情 | 详情 | |
| (III) | 40015 | 3-bromo-2-methyl-1-propene | 1458-98-6 | C4H7Br | 详情 | 详情 |
| (IV) | 44117 | methyl (2R)-2-[(1R)-1-hydroxybutyl]-4-methyl-4-pentenoate | C11H20O3 | 详情 | 详情 | |
| (V) | 44118 | methyl (2R,3R)-3-hydroxy-2-isobutylhexanoate | C11H22O3 | 详情 | 详情 | |
| (VI) | 44119 | (2R,3R)-3-hydroxy-2-isobutylhexanoic acid | C10H20O3 | 详情 | 详情 | |
| (VII) | 44120 | (2R,3R)-3-hydroxy-2-isobutyl-N-(tetrahydro-2H-pyran-2-yloxy)hexanamide | C15H29NO4 | 详情 | 详情 | |
| (VIII) | 44121 | (1R,2R)-4-methyl-1-propyl-2-[[(tetrahydro-2H-pyran-2-yloxy)amino]carbonyl]pentyl methanesulfonate | C16H31NO6S | 详情 | 详情 | |
| (IX) | 44122 | (3R,4S)-3-isobutyl-4-propyl-1-(tetrahydro-2H-pyran-2-yloxy)-2-azetidinone | C15H27NO3 | 详情 | 详情 | |
| (X) | 44123 | (2R,3S)-2-isobutyl-3-[(tetrahydro-2H-pyran-2-yloxy)amino]hexanoic acid | C15H29NO4 | 详情 | 详情 | |
| (XI) | 44124 | (2R,3S)-3-[formyl(tetrahydro-2H-pyran-2-yloxy)amino]-2-isobutylhexanoic acid | C16H29NO5 | 详情 | 详情 |
合成路线5
该中间体在本合成路线中的序号：(II)The alkylation of diethyl (R)(+)-2-hydroxysuccinate (I) with 2-methylallyl bromide (II) by means of LiHMDS in THF gives the alkylated diester (III), which is hydrolyzed with KOH in dioxane/water to yield the chiral succinic acid (IV). The regioselective monoesterification of (IV) with benzyl alcohol (V), trifluoroacetic anhydride, TEA and DMAP affords the monobenzyl ester (VI). The lactonization of (VI) by means of bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BOPC) in dichloromethane provides the beta lactone (VII), which is hydrogenolyzed at the benzyl ester group by means of H2 over Pd/C in ethanol to give the carboxylic acid (VIII). Finally this compound is condensed with the dipeptide N2-(tert-butoxycarbonyl-L-alanyl)-N1-(1-naphthylmethyl)-L-lysinamide (IX) by means of DCC and HOBt in dichloromethane to yield the target dipeptide derivative.
| 【1】 Yamaguchi, H.; Kanda, Y.; Ikeda, S.; Akinaga, S.; Yamashita, Y.; Asai, A.; Mizukami, T. (Kyowa Hakko Kogyo Co., Ltd.); Proteasome inhibitors. EP 1166781; WO 0043000 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 57386 | diethyl (2R)-2-hydroxybutanedioate | C8H14O5 | 详情 | 详情 | |
| (II) | 40015 | 3-bromo-2-methyl-1-propene | 1458-98-6 | C4H7Br | 详情 | 详情 |
| (III) | 57387 | diethyl (2R,3S)-2-hydroxy-3-(2-methyl-2-propenyl)butanedioate | C12H20O5 | 详情 | 详情 | |
| (IV) | 57388 | (2R,3S)-2-hydroxy-3-(2-methyl-2-propenyl)butanedioic acid | C8H12O5 | 详情 | 详情 | |
| (V) | 18710 | Benzyl alcohol; Phenylmethanol | 100-51-6 | C7H8O | 详情 | 详情 |
| (VI) | 57389 | (2S)-2-[(1R)-2-(benzyloxy)-1-hydroxy-2-oxoethyl]-4-methyl-4-pentenoic acid | C15H18O5 | 详情 | 详情 | |
| (VII) | 57390 | benzyl (2R,3S)-3-(2-methyl-2-propenyl)-4-oxo-2-oxetanecarboxylate | C15H16O4 | 详情 | 详情 | |
| (VIII) | 57391 | (2R,3S)-3-isobutyl-4-oxo-2-oxetanecarboxylic acid | C8H12O4 | 详情 | 详情 | |
| (IX) | 57392 | tert-butyl (1S)-2-[((1S)-5-amino-1-{[(1-naphthylmethyl)amino]carbonyl}pentyl)amino]-1-methyl-2-oxoethylcarbamate | C25H36N4O4 | 详情 | 详情 |
合成路线6
该中间体在本合成路线中的序号：(IV)Noroxymorphindole (III) was prepared by Fischer indole synthesis from noroxymorphone (I) and phenylhydrazine (II) under acidic conditions. Alkylation of (III) with 2-methyl-2-propenyl bromide (IV) in the presence of NaHCO3 in DMF afforded the title compound.
| 【1】 McLamore, S.; et al.; Effect of N-alkyl and N-alkenyl substituents in noroxymorphindole, 17-substituted-6,7-dehydro-4,5alpha-epoxy-3,14-dihydroxy-6,7:2',3'-indolomorphinans on opioid receptor affinity, selectivity, and efficacy. J Med Chem 2001, 44, 9, 1471. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 33927 | (1S,5R,13R,17S)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0(1,13).0(5,17).0(7,18)]octadeca-7(18),8,10-trien-14-one | C16H17NO4 | 详情 | 详情 | |
| (II) | 11818 | Phenyl hydrazine; 1-Phenylhydrazine | 100-63-0 | C6H8N2 | 详情 | 详情 |
| (III) | 50974 | (1S,2S,13R,21R)-14-oxa-11,22-diazaheptacyclo[13.9.1.0(1,13).0(2,21).0(4,12).0(5,10).0(19,25)]pentacosa-4(12),5,7,9,15(25),16,18-heptaene-2,16-diol | C22H20N2O3 | 详情 | 详情 | |
| (IV) | 40015 | 3-bromo-2-methyl-1-propene | 1458-98-6 | C4H7Br | 详情 | 详情 |
合成路线7
该中间体在本合成路线中的序号：(IX)The hydrolysis of Zofimarin (I) with NaOMe in methanol gives the sodium salt of the deacylated compound (II), which is treated with Pmb-Cl in DMF to yield the p-methoxybenzyl ester (III). The protection of the formyl group of (III) by means of ethyleneglycol, trimethyl orthoformate and TsOH affords the ethylene ketal (IV), which is oxidized at the vicinal diol group by means of NaIO4 in methanol/water to provide the dialdehyde (V). The reductocyclization of (V) with allylamine (VI) by means of NaBH3CN and AcOH in acetonitrile leads to the perhydro oxazepine derivative (VII), which is deallylated by means of Rh(PPh3)3Cl in aqueous ethanol to give compound (VIII). The alkylation of (VIII) with 2-methylallyl bromide (IX) by means of NaHCO3 and NaI in ethanol yields the protected precursor (X), which is finally treated with TFA in dichloromethane to provide the target zofimarin derivative.
| 【1】 Fukuoka, T.; Kamai, Y.; Kakuta, M.; Kaneko, S.; Arai, M.; Uchida, T.; Konosu, T.; Kuwahara, S.; Design, synthesis, and in vitro activity of RS-135853, a novel zofimarin-related antifungal agent. 42nd Intersci Conf Antimicrob Agents Chemother (Sept 27 2002, San Diego) 2002, Abst F-824. |
| 【2】 Kaneko, S.; Uchida, T.; Arai, M.; Kounosu, T. (Sankyo Co., Ltd.); Zofimarin derivs. having an oxazepan ring. JP 2002161086; WO 0223541 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 60326 | (1R,2S,4R,5R,8R,9S)-9-formyl-2-[({(2R,3S,4S,5R,6R)-4-[(2Z,4E)-2,4-hexadienoyloxy]-3-hydroxy-5-methoxy-6-methyltetrahydro-2H-pyran-2-yl}oxy)methyl]-13-isopropyl-5-methyltetracyclo[7.4.0.0~2,11~.0~4,8~]tridec-12-ene-1-carboxylic acid | C33H46O9 | 详情 | 详情 | |
| (II) | 59613 | (1R,2S,4R,5R,8R,9S,11R)-2-({[(2R,3S,4S,5S,6R)-3,4-dihydroxy-5-methoxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}methyl)-9-formyl-13-isopropyl-5-methyltetracyclo[7.4.0.0~2,11~.0~4,8~]tridec-12-ene-1-carboxylic acid | C27H40O8 | 详情 | 详情 | |
| (III) | 60327 | 4-methoxybenzyl (1R,2S,4R,5R,8R,9S)-2-({[(2R,3S,4S,5S,6R)-3,4-dihydroxy-5-methoxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}methyl)-9-formyl-13-isopropyl-5-methyltetracyclo[7.4.0.0~2,11~.0~4,8~]tridec-12-ene-1-carboxylate | C35H48O9 | 详情 | 详情 | |
| (IV) | 60328 | 4-methoxybenzyl (1R,2S,4R,5R,8R,9S)-2-({[(2R,3S,4S,5S,6R)-3,4-dihydroxy-5-methoxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}methyl)-9-(1,3-dioxolan-2-yl)-13-isopropyl-5-methyltetracyclo[7.4.0.0~2,11~.0~4,8~]tridec-12-ene-1-carboxylate | C37H52O10 | 详情 | 详情 | |
| (V) | 60329 | 4-methoxybenzyl (1R,2S,4R,5R,8R,9S)-9-(1,3-dioxolan-2-yl)-13-isopropyl-2-{[((1R)-1-{[(1R,2R)-2-methoxy-1-methyl-3-oxopropyl]oxy}-2-oxoethyl)oxy]methyl}-5-methyltetracyclo[7.4.0.0~2,11~.0~4,8~]tridec-12-ene-1-carboxylate | C37H50O10 | 详情 | 详情 | |
| (VI) | 13672 | Allylamine; 2-Propen-1-amine | 107-11-9 | C3H7N | 详情 | 详情 |
| (VII) | 60330 | 4-methoxybenzyl (1R,2S,4R,5R,8R,9S)-2-({[(2R,6S,7R)-4-allyl-6-methoxy-7-methyl-1,4-oxazepan-2-yl]oxy}methyl)-9-(1,3-dioxolan-2-yl)-13-isopropyl-5-methyltetracyclo[7.4.0.0~2,11~.0~4,8~]tridec-12-ene-1-carboxylate | C40H57NO8 | 详情 | 详情 | |
| (VIII) | 60331 | 4-methoxybenzyl (1R,2S,4R,5R,8R,9S)-9-(1,3-dioxolan-2-yl)-13-isopropyl-2-({[(2R,6S,7R)-6-methoxy-7-methyl-1,4-oxazepan-2-yl]oxy}methyl)-5-methyltetracyclo[7.4.0.0~2,11~.0~4,8~]tridec-12-ene-1-carboxylate | C37H53NO8 | 详情 | 详情 | |
| (IX) | 40015 | 3-bromo-2-methyl-1-propene | 1458-98-6 | C4H7Br | 详情 | 详情 |
| (X) | 60332 | 4-methoxybenzyl (1R,2S,4R,5R,8R,9S)-9-(1,3-dioxolan-2-yl)-13-isopropyl-2-({[(2R,6S,7R)-6-methoxy-7-methyl-4-(2-methyl-2-propenyl)-1,4-oxazepan-2-yl]oxy}methyl)-5-methyltetracyclo[7.4.0.0~2,11~.0~4,8~]tridec-12-ene-1-carboxylate | C41H59NO8 | 详情 | 详情 |